Clinical Implications of Serum Mac-2 Binding Protein in Patients After Living Donor Liver Transplantation for Biliary Atresia

被引:0
|
作者
Ueno, Takehisa [1 ]
Takase, Koki [1 ]
Deguchi, Koichi [1 ]
Nomura, Motonari [1 ]
Watanabe, Miho [1 ]
Kamiyama, Masafumi [1 ]
Tazuke, Yuko [1 ]
Kimura, Takeshi [2 ]
Okuyama, Hiroomi [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Pediat Surg, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Pediat, Suita, Japan
关键词
PORTAL-VEIN COMPLICATIONS; SIMPLE NONINVASIVE INDEX; VENOUS COMPLICATIONS; SIGNIFICANT FIBROSIS; PREDICT; SIZE;
D O I
10.1016/j.transproceed.2024.01.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Patients who undergo pediatric living donor liver transplantation (LDLT) sometimes develop graft fibrosis. Recently, Mac -2 binding protein glycosylation-modified isomer (M2BPGi) was developed as a new marker of hepatic fibrosis progression. We performed this study to examine the relationship between serum M2BPGi levels and liver histologic findings in patients after LDLT for biliary atresia. Methods. Patients aged <19 years who underwent LDLT for biliary atresia at our institution and followed up for at least 1 year after LDLT were eligible. There were 56 patients in this study. Pathologic findings of the last available biopsy were assessed. Portal vein (PV) stenosis was confirmed with angiography. M2BPGi levels were compared with pathologic fibrosis scores and PV stenosis findings. Results. The mean age at transplant was 4.3 years. The mean observation period was 8.6 years. In terms of the degree of liver fibrosis, F0 was observed in 7 patients, F1 in 36, and F2 in 13. The median serum M2BPGi value was 0.8 cut-off index (COI) overall and 0.60 COI for F0, 0.74 COI for F1, and 1.07 COI for F2. The mean M2BPGi value in F2 was higher than that in F0 (P = .016) and F1 (P = .012). Mean serum M2BPGi values were 1.57 COI (0.29 COI) in patients with PV complications (n = 5) and 0.72 COI in patients without PV complications (n = 51) (P = .0001). Conclusion. M2BPGi is a novel marker for liver fibrosis in patients after pediatric LDLT. It is especially useful for follow-up of pediatric patients after LDLT to support liver biopsy interpretation.
引用
收藏
页码:343 / 347
页数:5
相关论文
共 50 条
  • [31] Biliary Complications and Management in Pediatric Living Donor Liver Transplantation for Underlying Biliary Atresia
    Lu, C. -H.
    Tsang, L. L. -C.
    Huang, T. -L.
    Chen, T. -Y.
    Ou, H. -Y.
    Yu, C. -Y.
    Chen, C. -L.
    Cheng, Y. -F.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (02) : 476 - 477
  • [32] Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis
    Takehisa Ueno
    Tasuku Kodama
    Yuki Noguchi
    Motonari Nomura
    Ryuta Saka
    Yuichi Takama
    Yuko Tazuke
    Kazuhiko Bessho
    Hiroomi Okuyama
    Pediatric Surgery International, 2019, 35 : 1065 - 1070
  • [33] Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis
    Ueno, Takehisa
    Kodama, Tasuku
    Noguchi, Yuki
    Nomura, Motonari
    Saka, Ryuta
    Takama, Yuichi
    Tazuke, Yuko
    Bessho, Kazuhiko
    Okuyama, Hiroomi
    PEDIATRIC SURGERY INTERNATIONAL, 2019, 35 (10) : 1065 - 1070
  • [34] Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases
    Tamaki, Nobuharu
    Kurosaki, Masayuki
    Loomba, Rohit
    Izumi, Namiki
    ANNALS OF LABORATORY MEDICINE, 2021, 41 (01) : 16 - 24
  • [35] Biliary Complications After Living Donor Liver Transplantation
    Wang, Shao Fa
    Huang, Zhi Yong
    Chen, Xiao Ping
    LIVER TRANSPLANTATION, 2011, 17 (10) : 1127 - 1136
  • [36] Intellectual development of patients with biliary atresia who underwent living donor liver transplantation in infancy
    Kawabata, Seiichi
    Sakamoto, Rieko
    Uto, Keiichi
    Irie, Tomoaki
    Kadohisa, Masashi
    Shimata, Keita
    Narita, Yasuko
    Isono, Kaori
    Honda, Masaki
    Hayashida, Shintaro
    Ohya, Yuki
    Yamamoto, Hidekazu
    Yamamoto, Hirotoshi
    Nakano, Miwako
    Sugawara, Yasuhiko
    Inomata, Yukihiro
    Hibi, Taizo
    PEDIATRIC SURGERY INTERNATIONAL, 2022, 38 (02) : 201 - 208
  • [37] Can Primary Living Donor Liver Transplantation Be the First Line Treatment for Patients with Biliary Atresia?
    Wang, Qiao
    Yan, Lunan
    Zhang, Mingman
    Wang, Wentao
    Zhao, Jichun
    Pu, Conglun
    Li, Yingcun
    Kang, Quan
    LIVER TRANSPLANTATION, 2012, 18 : S113 - S114
  • [38] Intellectual development of patients with biliary atresia who underwent living donor liver transplantation in infancy
    Seiichi Kawabata
    Rieko Sakamoto
    Keiichi Uto
    Tomoaki Irie
    Masashi Kadohisa
    Keita Shimata
    Yasuko Narita
    Kaori Isono
    Masaki Honda
    Shintaro Hayashida
    Yuki Ohya
    Hidekazu Yamamoto
    Hirotoshi Yamamoto
    Miwako Nakano
    Yasuhiko Sugawara
    Yukihiro Inomata
    Taizo Hibi
    Pediatric Surgery International, 2022, 38 : 201 - 208
  • [39] Pediatric living donor liver transplantation for biliary atresia versus non-biliary atresia: Is there a difference in outcome?
    Wang, Shih-Ho
    Chen, Chao-Long
    Wang, Chih-Chi
    Concejero, Allan M.
    Lin, Chih-Che
    Liu, Yeuh-Wei
    Yong, Chee-Chien
    Yang, Chin-Hsiang
    Lin, Tsan-Shiun
    Chiang, Yuan-Cheng
    TRANSPLANT INTERNATIONAL, 2007, 20 : 314 - 314
  • [40] THE OUTCOME OF LIVING DONOR LIVER TRANSPLANTATION FOR BILIARY ATRESIA : THE COMPARISON OF ADULTS AND CHILDREN
    Hayashida, Makoto
    Yanagi, Yusuke
    Esumi, Genshiro
    Ikegami, Toru
    Yoshizumi, Tomoharu
    Soejima, Yuji
    Shirabe, Ken
    Maehara, Yoshihiko
    Taguchi, Tomoaki
    PEDIATRIC TRANSPLANTATION, 2013, 17 : 100 - 100